# Phase Ib Study of Chiauranib in Patients With Ovarian Cancer

> **NCT03166891** · PHASE1,PHASE2 · COMPLETED · sponsor: **Chipscreen Biosciences, Ltd.** · enrollment: 25 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Chiauranib

## Key facts

- **NCT ID:** NCT03166891
- **Lead sponsor:** Chipscreen Biosciences, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-15
- **Primary completion:** 2019-03-20
- **Final completion:** 2019-03-20
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2020-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03166891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03166891, "Phase Ib Study of Chiauranib in Patients With Ovarian Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03166891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*